» Articles » PMID: 7707420

Effects of Individualized Breast Cancer Risk Counseling: a Randomized Trial

Overview
Specialty Oncology
Date 1995 Feb 15
PMID 7707420
Citations 122
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies have shown that a majority of women with a family history of breast cancer have exaggerated perceptions of their own risk of this disease and experience excessive anxiety. In response to the need to communicate more accurate risk information to these women, specialized programs for breast cancer risk counseling have been initiated in medical centers across the United States.

Purpose: Our purpose was 1) to evaluate the impact of a standardized protocol for individualized breast cancer risk counseling on comprehension of personal risk among first-degree relatives of index breast cancer patients and 2) to identify women most and least likely to benefit from such counseling.

Methods: This study is a prospective randomized trial comparing individualized breast cancer risk counseling to general health counseling (control). We studied 200 women aged 35 years and older who had a family history of breast cancer in a first-degree relative. Women with a personal history of cancer were excluded. Risk comprehension was assessed as the concordance between perceived "subjective" lifetime breast cancer risk and estimated "objective" lifetime risk.

Results: The results of logistic regression analysis showed that women who received risk counseling were significantly more likely to improve their risk comprehension, compared with women in the control condition (odds ratio [OR] = 3.5; 95% confidence interval [CI] = 1.3-9.5; P = .01). However, in both groups, about two thirds of women continued to overestimate their lifetime risks substantially following counseling. Examination of subjects by treatment interaction effects indicated that risk counseling did not produce improved comprehension among the large proportion of women who had high levels of anxious preoccupation with breast cancer at base line (P = .02). In addition, white women were less likely to benefit than African-American women (OR = 0.34; 95% CI = 0.11-0.99; P = .05).

Conclusion: Efforts to counsel women about their breast cancer risks are not likely to be effective unless their breast cancer anxieties are also addressed.

Implications: Attention to the psychological aspects of breast cancer risk will be critical in the development of risk-counseling programs that incorporate testing for the recently cloned breast cancer susceptibility gene, BRCA1 (and BRCA2 when that gene has also been cloned).

Citing Articles

Factors associated with adherence to BRCA1/2 mutation testing after oncogenetic counseling in long-surviving patients with a previous diagnosis of breast or ovarian cancer.

Actis S, DAlonzo M, Pace L, Mucciacito S, Bounous V, Sgro L J Community Genet. 2023; 14(6):649-656.

PMID: 37723374 PMC: 10725406. DOI: 10.1007/s12687-023-00671-x.


Breast/ovarian cancer genetic counseling: Do anxiety, depression, and health care-related fears influence cancer worry and risk perception?.

Caruso A, Maggi G, Vigna C, Savarese A, Gallo L, Guariglia L Cancer Med. 2023; 12(18):19215-19224.

PMID: 37706348 PMC: 10557864. DOI: 10.1002/cam4.6518.


The predictive role of intolerance of uncertainty and trait of worry in breast cancer patients: A prospective, observational, single-center clinical study.

Shams M, Pardini S, Del Bianco P, Calabrese C, De Salvo G, Novara C Front Psychol. 2023; 14:1092060.

PMID: 37138973 PMC: 10149753. DOI: 10.3389/fpsyg.2023.1092060.


Testing Explanations for Skepticism of Personalized Risk Information.

Waters E, Taber J, Ackermann N, Maki J, McQueen A, Scherer L Med Decis Making. 2023; 43(4):430-444.

PMID: 37005827 PMC: 10164692. DOI: 10.1177/0272989X231162824.


How do women who are informed that they are at increased risk of breast cancer appraise their risk? A systematic review of qualitative research.

Woof V, Howell A, McWilliams L, Evans D, French D Br J Cancer. 2022; 127(11):1916-1924.

PMID: 36002751 PMC: 9681857. DOI: 10.1038/s41416-022-01944-x.